210 related articles for article (PubMed ID: 9826579)
1. CD30: expression and function in health and disease.
Horie R; Watanabe T
Semin Immunol; 1998 Dec; 10(6):457-70. PubMed ID: 9826579
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of CD30 on T lymphocytes.
Tarkowski M
Arch Immunol Ther Exp (Warsz); 1999; 47(4):217-21. PubMed ID: 10483869
[TBL] [Abstract][Full Text] [Related]
3. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
5. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
6. CD30 in normal and neoplastic cells.
Chiarle R; Podda A; Prolla G; Gong J; Thorbecke GJ; Inghirami G
Clin Immunol; 1999 Feb; 90(2):157-64. PubMed ID: 10080826
[TBL] [Abstract][Full Text] [Related]
7. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
[TBL] [Abstract][Full Text] [Related]
8. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
9. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells.
Horie R; Watanabe T; Morishita Y; Ito K; Ishida T; Kanegae Y; Saito I; Higashihara M; Mori S; Kadin ME; Watanabe T
Oncogene; 2002 Apr; 21(16):2493-503. PubMed ID: 11971184
[TBL] [Abstract][Full Text] [Related]
10. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
11. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications.
de Bruin PC; Gruss HJ; van der Valk P; Willemze R; Meijer CJ
Leukemia; 1995 Oct; 9(10):1620-7. PubMed ID: 7564499
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD30 ligand (CD153) on murine activated T cells.
Shimozato O; Takeda K; Yagita H; Okumura K
Biochem Biophys Res Commun; 1999 Mar; 256(3):519-26. PubMed ID: 10080930
[TBL] [Abstract][Full Text] [Related]
13. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
14. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Kobata T; Yagita H; Okumura K; Azuma M; Yazaki Y
J Pathol; 1999 Aug; 188(4):423-30. PubMed ID: 10440754
[TBL] [Abstract][Full Text] [Related]
15. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
16. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily.
Boucher LM; Marengère LE; Lu Y; Thukral S; Mak TW
Biochem Biophys Res Commun; 1997 Apr; 233(3):592-600. PubMed ID: 9168896
[TBL] [Abstract][Full Text] [Related]
17. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.
Pellegrini P; Berghella AM; Contasta I; Adorno D
Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032
[TBL] [Abstract][Full Text] [Related]
18. The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter.
Dürkop H; Oberbarnscheidt M; Latza U; Bulfone-Paus S; Hirsch B; Pohl T; Krause H; Hummel M; Stein H
J Pathol; 2000 Oct; 192(2):182-93. PubMed ID: 11004694
[TBL] [Abstract][Full Text] [Related]
19. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
20. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
